# Imatinib Mesylate in Treating Patients With Recurrent Meningioma

> **NCT00045734** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 23 (actual)

## Conditions studied

- Adult Grade I Meningioma
- Adult Grade II Meningioma
- Adult Grade III Meningioma
- Adult Meningeal Hemangiopericytoma
- Adult Meningioma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** imatinib mesylate
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00045734
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2009-12
- **Final completion:** 2009-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2017-05-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00045734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00045734, "Imatinib Mesylate in Treating Patients With Recurrent Meningioma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00045734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*